A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Moderate to Severe Atopic Dermatitis
Latest Information Update: 08 Mar 2026
At a glance
- Drugs Galvokimig (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors UCB Biopharma
Most Recent Events
- 28 Jan 2026 Planned End Date changed from 1 Mar 2028 to 6 Mar 2028.
- 28 Jan 2026 Planned primary completion date changed from 1 May 2027 to 17 May 2027.
- 28 Jan 2026 Status changed from not yet recruiting to recruiting.